Deus Technologies will file for premarket approval of an x-ray CAD early-stage lung cancer detection system, joining a growing list of companies that are concentrating on this disease. The product will debut at the RSNA meeting.The stand-alone system,
Deus Technologies will file for premarket approval of an x-ray CAD early-stage lung cancer detection system, joining a growing list of companies that are concentrating on this disease. The product will debut at the RSNA meeting.
The stand-alone system, called RapidScreen RS-2000, uses image processing and feature extraction technology originally employed in the analysis of satellite remote-sensing images. It analyzes regions of interest that may have features associated with solitary pulmonary nodules.
The proprietary algorithms are based on a combination of image processing, neural network, and fuzzy logic techniques developed from a database of thousands of chest films of early-stage lung cancer and cancer-free cases.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.